18:32 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Biogen's aducanumab shows continued improvements through 48 weeks in Phase Ib extension for Alzheimer’s

Biogen Inc. (NASDAQ:BIIB) reported additional data from the long-term extension of the Phase Ib PRIME trial to treat prodromal or mild Alzheimer’s disease showing that aducanumab (BIIB037) continued to reduce amyloid plaque levels through 48...
18:53 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

Biogen, Eisai's elenbecestat reduces plaques, slows AD progression in Phase II

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) reported data from the Phase II Study 202 for their β-site APP-cleaving enzyme 1 (BACE1) inhibitor elenbecestat (E2609) showing that the therapy reduced amyloid plaques and slowed...
21:25 , Nov 10, 2017 |  BC Week In Review  |  Clinical News

Biogen reports Phase Ib extension data for aducanumab in AD

Biogen Inc. (NASDAQ:BIIB) reported 24- and 36-month data from a long-term extension of the Phase Ib PRIME trial to treat prodromal or mild Alzheimer’s disease showing that aducanumab (BIIB037) continued to reduce amyloid plaque levels,...
22:35 , Nov 2, 2017 |  BC Extra  |  Clinical News

Biogen reports Phase Ib extension data for aducanumab in AD

Biogen Inc. (NASDAQ:BIIB) reported 24- and 36-month data from a long-term extension of the Phase Ib PRIME trial to treat prodromal or mild Alzheimer’s disease showing that aducanumab (BIIB037) continued to reduce amyloid plaque levels,...
22:57 , Sep 29, 2017 |  BC Extra  |  Company News

Eli Lilly management changes

Eli Lilly and Co. (NYSE:LLY) announced several managerial changes on Friday, including the promotion of SVP of Clinical and Product Development Dan Skovronsky to SVP for science and technology and president of Lilly Research Labs...
20:27 , Dec 16, 2016 |  BC Week In Review  |  Clinical News

Aducanumab: Updated Ph Ib PRIME data

Data from 197 patients with prodromal or mild AD in the double-blind, dose-escalation, U.S. Phase Ib PRIME trial showed that 1, 3, 6 and 10 mg/kg IV aducanumab significantly reduced mean levels of amyloid plaque,...
07:00 , Oct 24, 2016 |  BioCentury  |  Strategy

Lilly’s history lesson

  Eli Lilly and Co. President and CEO-in-waiting David Ricks will inherit a well-stocked pipeline, seven drugs less than three years old and a much-improved growth trajectory. To maintain momentum, he’ll have to execute on...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Clinical News

Amyvid florbetapir: Clinical trial data

A study in 618 patients being evaluated for cognitive decline showed that PET imaging with Amyvid led to treatment management changes in 68% of patients in the immediate-feedback group vs. 56% of patients in the...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Clinical News

Aducanumab: Updated Phase Ib data

Updated data from 166 patients with prodromal or mild AD in the double-blind, dose-escalation, U.S. Phase Ib PRIME trial showed that 3, 6 and 10 mg/kg IV aducanumab significantly reduced mean levels of amyloid plaque,...
01:13 , Jul 24, 2015 |  BC Extra  |  Clinical News

Lilly study links Amyvid to changes in treatment

Eli Lilly and Co. (NYSE:LLY) presented data showing that knowledge of amyloid status measured by PET imaging agent Amyvid florbetapir led to changes in the diagnosis and management of patients being evaluated for cognitive decline....